Clinical analysis of advanced NSCLC treated by endostar in combination with NP

Chun Huang, Kai Li

    Research output: Contribution to journalArticle

    2 Scopus citations


    Objective: To investigate the the short term efficacy and safety of YH-16 plus NP in the treatment of non-small cell lung cancer (NSCLC). Methods: Eleven patients with advanced NSCLC were treated by YH-16 plus NP. The efficacies and toxicities of the patients were analyzed and their numbers of CECs were measured by flow cytometry. Results: Of 11 assessable cases, 1 patient achieved PR, 7 patients got SD and 3 patients got PD. In the untreated 3 patients, one achieved PR and the other two got SD. In the pretreated 9 patients, 3 second-line patients treated by YH-16 plus NP all got SD; 3 third-line patients got 2 SD and I PD; 2 fourth-line patients both got PD. During the treatment, besides I-II myelo-supression and nausea/vomiting, mild heart dysfunction and fatigue were found in some patients. No treatment of YH-16 plus NP were discontinued due to the toxicities. The number of CECs decreased from (0.67 ± 0.20)% to (0.43 ± 0.20)% in 7 patients in benefit, while it increased from (0.69 ±0.25)% to (1.08± 0.63)% in 4 patients out of benefit. Conclusions. YH-16 plus NP is a good regimen for untreated advariced NSCLC patients, and it possibly benefits the failures pretreated by first-line or multi-line Cisplatin combinations. YH-16 in combination with NP chemotherapy shows a synergic activity and a favorable toxic profile in advanced NSCLC patients. CECs could be a good marker to predict the efficacy of anti-angiogenesis therapy combined with chemotherapy.

    Original languageEnglish (US)
    Pages (from-to)283-285
    Number of pages3
    JournalChinese Journal of Cancer Prevention and Treatment
    Issue number4
    StatePublished - Feb 28 2008


    • Angiogenesis inhibitors
    • Blood circulation
    • Carcinoma, non-small cell lung/drug therapy
    • Endostatins
    • Endothelium, rascular/cytology

    ASJC Scopus subject areas

    • Oncology

    Fingerprint Dive into the research topics of 'Clinical analysis of advanced NSCLC treated by endostar in combination with NP'. Together they form a unique fingerprint.

  • Cite this